Morgan Stanley Innate Pharma Sa Put Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
10Shares Held
99.8KCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il26.6KShares$53,7660.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7KShares$23,5550.0% of portfolio
-
Ubs Group Ag5.96KShares$12,0330.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.46KShares$6,9810.0% of portfolio
-
Rhumbline Advisers Boston, MA470Shares$9490.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $161M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...